254 related articles for article (PubMed ID: 10572352)
1. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Brown MC; Nimmerrichter AA; Guest JF
Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
Borghi J; Guest JF
Eur Psychiatry; 2000 Sep; 15(6):378-87. PubMed ID: 11004733
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine. A pharmacoeconomic review of its use in depression.
Holm KJ; Jarvis B; Foster RH
Pharmacoeconomics; 2000 May; 17(5):515-34. PubMed ID: 10977391
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Lenox-Smith A; Greenstreet L; Burslem K; Knight C
Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective].
Norinder A; Nordling S; Häggström L
Lakartidningen; 2000 Apr; 97(14):1693-8, 1700. PubMed ID: 10815396
[TBL] [Abstract][Full Text] [Related]
6. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression.
Stahl S; Zivkov M; Reimitz PE; Panagides J; Hoff W
Acta Psychiatr Scand Suppl; 1997; 391():22-30. PubMed ID: 9265948
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Winokur A; DeMartinis NA; McNally DP; Gary EM; Cormier JL; Gary KA
J Clin Psychiatry; 2003 Oct; 64(10):1224-9. PubMed ID: 14658972
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
Hong CJ; Hu WH; Chen CC; Hsiao CC; Tsai SJ; Ruwe FJ
J Clin Psychiatry; 2003 Aug; 64(8):921-6. PubMed ID: 12927007
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.
Kasper S
Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():25-35. PubMed ID: 8930007
[TBL] [Abstract][Full Text] [Related]
14. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study.
Montgomery SA; Reimitz PE; Zivkov M
Int Clin Psychopharmacol; 1998 Mar; 13(2):63-73. PubMed ID: 9669186
[TBL] [Abstract][Full Text] [Related]
15. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
[TBL] [Abstract][Full Text] [Related]
17. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.
Versiani M; Ontiveros A; Mazzotti G; Ospina J; Dávila J; Mata S; Pacheco A; Plewes J; Tamura R; Palacios M
Int Clin Psychopharmacol; 1999 Nov; 14(6):321-7. PubMed ID: 10565798
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study.
Altintoprak AE; Zorlu N; Coskunol H; Akdeniz F; Kitapcioglu G
Hum Psychopharmacol; 2008 Jun; 23(4):313-9. PubMed ID: 18327889
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine: a review of its use in major depression.
Holm KJ; Markham A
Drugs; 1999 Apr; 57(4):607-31. PubMed ID: 10235695
[TBL] [Abstract][Full Text] [Related]
20. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.
Smith WT; Glaudin V; Panagides J; Gilvary E
Psychopharmacol Bull; 1990; 26(2):191-6. PubMed ID: 2236455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
